AU2003278369A1 - 3-cyano-quinoline derivatives - Google Patents

3-cyano-quinoline derivatives

Info

Publication number
AU2003278369A1
AU2003278369A1 AU2003278369A AU2003278369A AU2003278369A1 AU 2003278369 A1 AU2003278369 A1 AU 2003278369A1 AU 2003278369 A AU2003278369 A AU 2003278369A AU 2003278369 A AU2003278369 A AU 2003278369A AU 2003278369 A1 AU2003278369 A1 AU 2003278369A1
Authority
AU
Australia
Prior art keywords
cyano
quinoline derivatives
quinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003278369A
Other languages
English (en)
Inventor
Laurent Francois Andre Hennequin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003278369A1 publication Critical patent/AU2003278369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003278369A 2002-11-02 2003-10-28 3-cyano-quinoline derivatives Abandoned AU2003278369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0225579.2A GB0225579D0 (en) 2002-11-02 2002-11-02 Chemical compounds
GB0225579.2 2002-11-02
PCT/GB2003/004661 WO2004041811A1 (en) 2002-11-02 2003-10-28 3-cyano-quinoline derivatives

Publications (1)

Publication Number Publication Date
AU2003278369A1 true AU2003278369A1 (en) 2004-06-07

Family

ID=9947091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003278369A Abandoned AU2003278369A1 (en) 2002-11-02 2003-10-28 3-cyano-quinoline derivatives

Country Status (6)

Country Link
US (2) US7173136B2 (enExample)
EP (1) EP1575943A1 (enExample)
JP (1) JP2006508944A (enExample)
AU (1) AU2003278369A1 (enExample)
GB (1) GB0225579D0 (enExample)
WO (1) WO2004041811A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
WO2008135886A2 (en) * 2007-05-02 2008-11-13 University Of Pretoria Quinoline derivatives for use in the inhibition of the growth of tumour cells
RU2476582C2 (ru) 2007-11-19 2013-02-27 Шелл Интернэшнл Рисерч Маатсхаппий Б.В. Способ запуска каталитического процесса
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2012166654A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
WO2021242505A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (enExample) * 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
EP0584222B1 (en) * 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1993003030A1 (en) 1991-08-02 1993-02-18 Pfizer Inc. Quinoline derivatives as immunostimulants
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AU7340096A (en) * 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
CA2263479A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as vegf
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CN1165532C (zh) 1998-09-29 2004-09-08 惠氏控股有限公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR100821446B1 (ko) * 2000-08-21 2008-04-10 아스트라제네카 아베 퀴나졸린 유도체
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
WO2003047583A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
WO2003047584A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003047585A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
WO2003048159A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003047582A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives as antitumour agents
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
JP2005536486A (ja) 2002-07-09 2005-12-02 アストラゼネカ アクチボラグ 癌の処置に使用するためのキナゾリン誘導体
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
US9279144B2 (en) 2010-02-25 2016-03-08 Dana-Farber Cancer Institute, Inc. Screening method for BRAF inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
US7173136B2 (en) 2007-02-06
WO2004041811A1 (en) 2004-05-21
US20070191346A1 (en) 2007-08-16
JP2006508944A (ja) 2006-03-16
EP1575943A1 (en) 2005-09-21
US20050282856A1 (en) 2005-12-22
GB0225579D0 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
EP1682493B8 (en) Amidoacetonitrile derivatives
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2002335152A1 (en) Robot-phone
EP1606277B8 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
EP1706373B8 (en) Amidoacetonitrile derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2002367810A1 (en) Bis-transition-metal-chelate-probes
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2003238180A1 (en) 2-naphtamide derivatives
AU2003288012A1 (en) Isothiazolyl-benzoxazine derivatives
AU2003284704A1 (en) Substituted 1h-pyridine-2-one derivatives
AU2002318053A1 (en) Suplier
AU2002368348A1 (en) Electrosomatogram
AU2003243397A1 (en) Homo-camptothecin derivatives
AU2002348964A1 (en) Snowbike
AU2002341221A1 (en) Honey-brandy
AU2002344387A1 (en) Multifunction-pillow
HK1076608A (en) Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
AU2003284572A1 (en) 2-oxoindoline derivatives
AU2002100508A4 (en) Photocard

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase